title: [Juvenile idiopathic arthritis treated by methotrexate: result of treatment and tolerance].
abstract: The MTX has a place of choice in the treatment of the AJI with good observance and the absence of grave side effects. In a retrospective study, 14 cases of AJI having benefited from a treatment by MTX were included in the study. Answer to the treatment was estimated at the 6-th month on the criteria of RINTO. The group included in the therapeutic evaluation, is formed by 10 boys and by 4 girls. The average age of the beginning of the disease is of 6 years (2 - 11). The shape of the beginning is systematic in 7 cases and polyarticular in 5 cases and oligoarticular in 2 cases.. The average duration of the treatment by MTX is of 36 months (9 - 66). Answer to the MTX in the 6-th month was noted in 7 cases, under a MTX's average dose of 7, 14mg / m2 / week. Unwanted effects were observed in 7 cases and have not in any case led to the stop of the treatment
authors.affiliation: Service de Rhumatologie, Hôpital Mongi Slim, La Marsa, Tunis.
authors.forename: R
authors.initials: R
authors.lastname: Hajri
authors.forename: R
authors.initials: R
authors.lastname: Nasraoui
authors.forename: A
authors.initials: A
authors.lastname: Laatar
authors.forename: S
authors.initials: S
authors.lastname: Chekili
authors.forename: S
authors.initials: S
authors.lastname: Kassab
authors.forename: L
authors.initials: L
authors.lastname: Zakraoui
mesh_terms: D000367:Age Factors; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate